Telcare has announced that its product has been approved for sale and use in the E.U.
Telcare, Inc., a diabetes management solutions leader, has just announced that its CE Mark mhealth glucose meter device has received approval in the European Union for sale and use.
The smartphone enabled blood glucose meter (BGM) has already been approved by the FDA.
In fact, this product was the very first mhealth BGM to receive the clearance of the FDA. The announcement was made just in time for the World Health Conference and Exhibition. T his is important because it is at that event that the vice chairman, CEO, and founder of Telcare, Dr. Jonathan Javitt, is a featured presenter.
Javitt expressed the company’s excitement about the approval its mhealth device has received by the E.U.
He stated that “We are excited to expand our reach of innovative, comprehensive diabetes management solutions to the European Union.” He also went on to say that “Diabetes will affect one in three people born after the year 2000 and has reached pandemic proportions world-wide. Our mobile platform unlocks the power of clinical data and creates multiple engagement points amongst those involved in an individual’s care to help minimize complications and improve health outcomes.”
Technology Quotes That Invite Thought -
There have been over 360 million people who have are already living with the disease. It is predicted that by 2030, that number will have exploded to 552 million. Monitoring blood sugar levels every day is an important part of avoiding many of the complications that are associated with the condition. That said, the World Health Organization estimates that every day, there are 8,700 people who die from the disease.
The hope is that with mhealth devices that can be used through an individual’s smartphone, it will help to make monitoring blood sugar levels much more accessible and convenient to individuals with the condition. Telcare’s BGM is the very first of this type of device to receive approval by the FDA in the United States, as well as by the authorities in the European Union. If this trend is allowed to grow, it could make a meaningful difference in the care that diabetics can receive.